Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2022-05-02 Regulatory Filings
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the plans, incorporation by reference of previous filings, exhibits, and signatures of officers and directors. This type of filing is related to registering securities for employee compensation plans and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing specific to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement but a full registration statement filing.
2022-05-02 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Trevi Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for the resale of shares by selling stockholders. The document includes a prospectus summary, risk factors, use of proceeds, selling stockholders, plan of distribution, legal matters, and incorporation by reference sections. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or management discussion. It is a capital markets filing related to securities registration and resale. According to the filing definitions, updates on company fundraising, financing activities, or capital structure changes fall under Capital/Financing Update (CAP). A Form S-3 registration statement is a capital markets filing used to register securities for sale, which fits the CAP category best. The document is substantive and not a mere announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is Capital/Financing Update (CAP).
2022-05-02 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to the Securities Exchange Act of 1934. The text indicates it is a 'Definitive Additional Materials' filing related to a proxy statement for Trevi Therapeutics, Inc. Proxy statements and related materials are classified under Proxy Solicitation & Information Statement (PSI). The document length is short and it is not a full report but additional materials related to proxy solicitation, so it fits the PSI category rather than a full Annual Report or Remuneration Information report. Therefore, the correct classification is PSI with high confidence.
2022-05-02 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-29 English
NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS -- SCHEDULE 13D/A3
Major Shareholding Notification
2022-04-25 English
SC 13G
Major Shareholding Notification
2022-04-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.